TG Therapeutics (NASDAQ: TGTX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-01 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.510 | ||||||
REV | 2.016M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of TG Therapeutics (NASDAQ: TGTX) through any online brokerage.
Other companies in TG Therapeutics’s space includes: Avidity Biosciences (NASDAQ:RNA), Eagle Pharmaceuticals (NASDAQ:EGRX), Sangamo Therapeutics (NASDAQ:SGMO), PMV Pharma (NASDAQ:PMVP) and Kiniksa Pharmaceuticals (NASDAQ:KNSA).
The latest price target for TG Therapeutics (NASDAQ: TGTX) was reported by B. Riley Securities on Monday, June 13, 2022. The analyst firm set a price target for 17.00 expecting TGTX to rise to within 12 months (a possible 242.05% upside). 12 analyst firms have reported ratings in the last year.
The stock price for TG Therapeutics (NASDAQ: TGTX) is $4.97 last updated Today at July 5, 2022, 4:02 PM UTC.
There are no upcoming dividends for TG Therapeutics.
TG Therapeutics’s Q2 earnings are confirmed for Monday, August 1, 2022.
There is no upcoming split for TG Therapeutics.
TG Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.